Tg therapeutics, inc. (TGTX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Sep'11Jun'11Sep'10Jun'10
License revenue

38

38

38

38

38

38

38

38

38

38

38

38

38

37

38

38

38

38

38

38

38

38

38

38

38

38

38

38

38

19

0

0

0

-

-

-

-

Costs and expenses:
Research and development:
Non cash stock expense associated with in-licensing agreements

-

-

0

100

-

-

0

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,138

1,211

-

0

0

0

0

0

0

0

16,578

0

297

-

-

Noncash compensation

1,979

-

-

-

1,489

-

-

-

-

3,341

0

0

2,306

868

919

567

386

1,528

35

1,359

1,337

2,329

1,200

3,300

1,901

149

171

366

354

219

127

109

0

0

-

-

-

Noncash compensation

-

-

1,482

1,352

-

-

644

888

2,859

-

1,814

1,266

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other research and development

34,043

29,456

56,503

31,414

30,896

51,068

32,754

33,812

32,159

25,735

25,335

25,440

20,376

21,414

20,878

12,966

11,230

13,725

11,538

9,902

8,279

12,807

8,352

2,336

2,508

3,606

3,138

4,661

1,215

860

1,433

1,536

163

15

0

-

-

In-process research and development charge

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Loss on disposition of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

515

525

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total research and development

36,022

30,944

57,985

32,866

32,385

52,275

33,398

38,700

35,018

25,996

27,149

26,706

22,682

22,283

21,797

13,533

11,617

15,254

11,574

11,261

9,617

15,136

13,691

6,848

4,409

3,755

3,309

5,027

1,569

1,079

1,560

1,646

16,741

15

297

236

50

General and administrative:
Noncash compensation

9,089

4,132

593

405

393

252

-817

3,375

4,478

3,310

3,076

223

3,689

459

1,914

1,081

1,312

1,328

1,204

4,883

4,019

2,709

2,895

4,438

2,329

797

825

1,007

1,530

1,024

690

1,062

188

0

0

-

-

Other general and administrative

5,172

2,923

2,321

2,311

1,949

1,661

1,785

2,308

2,119

1,768

1,398

1,534

1,333

1,323

1,251

1,446

1,100

1,095

1,085

1,004

1,004

913

889

706

903

662

550

631

651

501

462

396

455

14

0

-

-

Total general and administrative

14,261

7,055

2,914

2,716

2,342

1,913

968

5,683

6,597

5,078

4,474

1,757

5,022

1,782

3,165

2,527

2,412

2,423

2,289

5,888

5,023

3,622

3,785

5,145

3,233

1,460

1,375

1,639

2,182

1,525

1,153

1,458

644

14

0

278

474

Impairment of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,104

0

0

0

-

-

-

-

Total costs and expenses

50,283

37,999

60,899

35,582

34,727

54,188

34,366

44,383

41,615

31,074

31,623

28,463

27,704

24,065

24,963

16,061

14,030

17,678

13,863

17,149

14,640

18,759

17,477

11,993

7,643

8,013

4,685

6,666

3,752

3,709

2,714

3,104

17,385

30

297

-

-

Operating loss

-50,245

-109,049

-60,861

35,544

-34,689

-142,840

-34,328

44,345

-41,577

-31,036

-31,585

-28,425

-27,666

-24,027

-24,925

-16,023

-13,992

-17,640

-13,825

-17,111

-14,602

-18,721

-17,439

-11,955

-7,605

-7,975

-4,647

-6,628

-3,714

-3,690

-2,714

-3,104

-17,385

-30

-297

-515

-525

Other (income) expense:
Equity in losses of Hedrin JV

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Gain on Nordic Settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-830

2,808

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-76

76

Interest expense

1,201

-

1,537

-

774

-

221

-

-

-

-

-

-

-

-

-

-

-

246

246

237

-

234

234

226

240

240

240

231

228

228

228

220

0

0

-349

351

Interest expense

-

-

-

1,077

-

-

-

223

144

-

79

50

45

57

87

92

84

64

55

31

22

16

12

12

13

15

12

1

1

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

4

4

3

0

0

-

-

Other income

330

288

468

408

307

867

598

426

-96

1,195

-30

22

-106

296

6

31

58

-

0

-

-

-210

0

0

95

108

0

0

0

0

0

272

0

0

0

-

-

Change in fair value of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

360

223

240

-

210

191

175

2,428

319

283

270

744

227

482

205

0

0

-

-

Total other expense (income), net

-871

-5,087

1,069

669

-467

1,044

-377

203

48

176

49

72

-61

353

94

124

143

28

169

8

25

-75

-11

-30

57

2,311

91

44

40

518

4

530

-11

0

0

-556

2,375

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,673

-3,172

-2,710

-2,574

-17,396

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

330

0

0

0

-

-

-

-

Net loss

-51,116

-111,998

-61,930

36,213

-35,156

-142,144

-33,951

44,142

-41,529

-30,860

-31,536

-28,353

-27,727

-23,674

-24,831

-15,899

-13,848

-17,611

-13,655

-17,103

-14,577

-18,796

-17,451

-11,986

-7,547

-5,663

-4,556

-6,584

-3,673

-3,502

-2,710

-2,574

-17,396

-30

-297

-

-

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-42

-247

-679

-7,140

-1

-14

-

-

Loss on early extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-159

Realized gain on sale of marketable equity securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to TG Therapeutics, Inc. and Subsidiaries

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,673

-3,459

-2,462

-1,894

-10,256

-28

-282

41

1,850

Preferred stock dividends (including imputed amounts)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income (loss) applicable to common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

1,850

Basic and diluted net loss per common share (in dollars per share)

-0.48

-1.26

-0.69

0.42

-0.43

-1.87

-0.43

0.59

-0.59

-0.46

-0.48

-0.45

-0.52

-0.49

-0.50

-0.33

-0.28

-0.37

-0.28

-0.38

-0.35

-0.52

-0.51

-0.36

-0.25

-0.19

-0.16

-0.29

-0.17

0.97

-0.16

-0.16

-2.03

-0.01

-0.15

0.02

0.77

Weighted average shares used in computing basic and diluted net loss per common share (in shares)

105,461

95,833

89,667

86,800

81,174

78,752

78,221

74,256

70,636

66,753

65,079

63,288

53,157

49,283

49,203

48,769

48,908

48,229

47,946

45,320

41,088

39,011

34,188

32,985

30,091

29,533

27,684

22,483

21,953

19,805

15,810

11,777

5,061

2,632

1,822

2,419

2,408